SS-31
10 mg
Research Use Only
For research use only. Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease. Must be 21 or older to purchase.
Measurement Key
mg = milligram; mcg = microgram; 1 mg = 1,000 mcg. mL = liquid volume. A U-100 syringe has 100 marked volume units per mL: one marking is 0.01 mL and ten are 0.10 mL. These markings are NOT peptide International Units (IU). A physical syringe may not have one-unit or half-unit graduations; do not imply it can measure a value more precisely than its scale permits. Concentration = total amount / measured FINAL volume. Quantity in a sample = concentration × sample volume. Required volume = a protocol-specified quantity / verified concentration. The calculator checks arithmetic only; it cannot select a clinical dose or establish suitability, stability or sterility.
Research Information
Contents
10 mg SS-31; small powder vial.
Clinical evidence and research limitations
Elamipretide, also called SS-31, has a specific approved prescription formulation, Forzinity, for improving muscle strength in a defined Barth syndrome population. Its accelerated approval is not proof of anti-aging, general energy or athletic benefits from this research vial.
Dosing evidence
Prescription-product reference only: Forzinity uses 40 mg subcutaneously daily in eligible patients weighing at least 30 kg, with renal-impairment modifications. It is an 80 mg/mL finished solution. That regimen and formulation are not instructions for this 10 mg powder vial.
Reconstitution
This is a powder-vial calculation reference, not a validated preparation recipe. Confirm the exact formulation, compatible diluent, final volume, container capacity, mixing method and storage with the manufacturer. Do not interpret the example as a direction to add that volume of BAC water.
Measurement example
MATHEMATICAL EXAMPLE ONLY: assuming 10 mg in a measured FINAL volume of 1 mL, concentration = 10 mg/mL. One U-100 marking (0.01 mL) represents 100 mcg. Ten U-100 markings (0.10 mL) represent 1 mg. These amounts describe the solution; they are not recommended doses. Use unrounded inputs for further calculations.
Possible side effects
Forzinity labeling reports local redness, pain, swelling/hardening, itching, bruising and hives; serious hypersensitivity can occur. These observations do not establish the safety of this research vial.
Storage
Follow the original lot-specific supplier instructions before and after preparation. Temperature, light protection, freezing limits and discard date: insufficient data to verify. The calculation volume does not establish stability or a use-by period.
Sources
Source access date: October 25, 2026. Secondary calculation references (peptidedosages.com) are community resources, not clinical trials. Their example volumes do not validate these products.
Responding to possible adverse effects: The side-effect summaries are incomplete and do not establish the safety of the inventory. Unknown risks must not be described as "no side effects." For anyone experiencing breathing difficulty, facial/throat swelling, fainting, severe persistent abdominal pain or other severe symptoms after an exposure, seek urgent medical care and provide the product/lot details.
Preparation and Handling Information
The original product instructions must establish substance identity, component ratio, excipients, compatible diluent, required amount, final volume, mixing method, container suitability, storage and discard interval. A 3 mL container does not automatically require 3 mL water. Any powder displacement and final-volume instructions must be accounted for. Do not transfer the storage rules for a branded finished medicine to a different research powder. No universal refrigerated shelf life, freezer shelf life or "28 days after mixing" period is established for this catalog. Lack of visible particles is not proof of sterility. Do not use a damaged, leaking, unexpectedly altered or undocumented preparation.